results
Jump to
89 Results Found
  • Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay Oct 14, 2019 04:07 PM IST

    Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay

    Net Sales are expected to increase by 2.4 percent Y-o-Y (up 13.8 percent Q-o-Q) to Rs. 2,642.7 crore, according to Emkay.

  • Glenmark Pharma Q1 PAT may dip 44.8% YoY to Rs. 151.7 cr: Prabhudas Lilladher Jul 12, 2019 05:00 PM IST

    Glenmark Pharma Q1 PAT may dip 44.8% YoY to Rs. 151.7 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.6 percent Y-o-Y (down 11 percent Q-o-Q) to Rs. 2,247.9 crore, according to Prabhudas Lilladher.

  • Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell May 31, 2019 11:34 AM IST

    Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell

    Elara Capital which has reduce rating on stock said FY19 operating performance remained weak, given lack of meaningful US sales.

  • Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher Apr 12, 2019 01:11 PM IST

    Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 10.8 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs. 2,490.2 crore, according to Prabhudas Lilladher.

  • Glenmark Q3 PAT seen up 96.7% YoY to Rs. 206.5 cr: Sharekhan Jan 18, 2019 02:45 PM IST

    Glenmark Q3 PAT seen up 96.7% YoY to Rs. 206.5 cr: Sharekhan

    Net Sales are expected to increase by 13.2 percent Y-o-Y (down 3.4 percent Q-o-Q) to Rs. 2,494 crore, according to Sharekhan.

  • Glenmark Q3 PAT seen up 121.5% YoY to Rs. 232 cr: ICICI Direct Jan 11, 2019 05:35 PM IST

    Glenmark Q3 PAT seen up 121.5% YoY to Rs. 232 cr: ICICI Direct

    Net Sales are expected to increase by 14.4 percent Y-o-Y (down 2.3 percent Q-o-Q) to Rs. 2,521 crore, according to ICICI Direct.

  • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila Jan 04, 2019 10:45 AM IST

    Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

    For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

  • Glenmark Pharma Q2 PAT seen up 2.8% YoY to Rs. 210 cr: HDFC Securities Oct 17, 2018 06:15 PM IST

    Glenmark Pharma Q2 PAT seen up 2.8% YoY to Rs. 210 cr: HDFC Securities

    Net Sales are expected to increase by 10.3 percent Y-o-Y (up 15.2 percent Q-o-Q) to Rs. 2,450 crore, according to HDFC Securities.

  • Glenmark Q2 PAT may dip 22% YoY to Rs. 167 cr: Sharekhan Oct 16, 2018 07:08 PM IST

    Glenmark Q2 PAT may dip 22% YoY to Rs. 167 cr: Sharekhan

    Net Sales are expected to increase by 5.1 percent Y-o-Y (up 9.5 percent Q-o-Q) to Rs. 2,372.4 crore, according to Sharekhan.

  • Glenmark Q2 PAT seen up 1.7% YoY to Rs. 217.8 cr: ICICI Direct Oct 12, 2018 04:43 PM IST

    Glenmark Q2 PAT seen up 1.7% YoY to Rs. 217.8 cr: ICICI Direct

    Net Sales are expected to increase by 12.6 percent Y-o-Y (up 17.3 percent Q-o-Q) to Rs. 2,540 crore, according to ICICI Direct.

  • Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz Jul 12, 2018 09:42 PM IST

    Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

    "For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

  • Glenmark Pharma Q4 PAT seen up 711.4% YoY to Rs. 170 cr: HDFC Securities Apr 20, 2018 01:33 PM IST

    Glenmark Pharma Q4 PAT seen up 711.4% YoY to Rs. 170 cr: HDFC Securities

    Net Sales are expected to decrease by 15 percent Y-o-Y (down 5.1 percent Q-o-Q) to Rs. 2,060 crore, according to HDFC Securities.

  • Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss Apr 16, 2018 06:07 PM IST

    Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss

    Net Sales are expected to decrease by 8.5 percent Y-o-Y (up 2 percent Q-o-Q) to Rs. 2,247.6 crore, according to Edelweiss.

  • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key Apr 12, 2018 05:53 PM IST

    Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

    Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

  • Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue Feb 09, 2018 10:44 AM IST

    Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue

    While addressing conference call, Glenn Saldanha, Chairman and MD said the US business continued to be very challenging and that pricing pressure would remain challenging for 5 quarters.

  • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key Jan 18, 2018 08:36 AM IST

    Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

    As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

  • Not looking at M&A as growth opportunity, would like to grow organically: Glenmark Nov 03, 2017 03:37 PM IST

    Not looking at M&A as growth opportunity, would like to grow organically: Glenmark

    Glenmark Pharma posted stable quarter with a slowdown seen in their Indian business. In an interview to CNBC-TV18, Glenn Saldanha, CMD of Glenmark spoke about the results and his outlook for the company.

  • Have buy rating on Glenmark Pharma: HDFC Securities Jul 28, 2017 11:37 AM IST

    Have buy rating on Glenmark Pharma: HDFC Securities

    In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about Q1 FY18 earnings from pharma sector.

  • Glenmark Pharma Q1 profit seen up 13% at Rs 257 cr, revenue growth may be 17% Jul 27, 2017 11:26 AM IST

    Glenmark Pharma Q1 profit seen up 13% at Rs 257 cr, revenue growth may be 17%

    Revenue growth is expected to be led by US business. Within US, street is factoring in a better performance from cholesterol drug Zetia generic that was launched in December with exclusivity; ended in June.

  • Glenmark Q4 PAT seen up 28.3% to Rs 590 cr: ICICI Securities Apr 17, 2017 01:33 PM IST

    Glenmark Q4 PAT seen up 28.3% to Rs 590 cr: ICICI Securities

    Net Sales are expected to increase by 14.5 percent Q-o-Q (up 27.2 percent Y-o-Y) to Rs 2902.7 crore, according to ICICI Securities. Glenmark to report net profit at 590 crore up 28.3% quarter-on-quarter.

  • Glenmark Q3 profit seen up 77%, US biz may lift revenue 33% Feb 02, 2017 10:37 AM IST

    Glenmark Q3 profit seen up 77%, US biz may lift revenue 33%

    For US business, the company may benefit from USD 2.6 billion worth Zetia generic, a cholesterol drug that launched with exclusivity on December 12 in US. Analysts expect the company to make USd 200-250 million from Zetia in 6 months.

  • Glenmark Pharma Q3 PAT seen up 37% to Rs 310 cr: HDFC Securities Jan 17, 2017 04:02 PM IST

    Glenmark Pharma Q3 PAT seen up 37% to Rs 310 cr: HDFC Securities

    Net Sales are expected to increase by 0.9 percent Q-o-Q (down 27.1 percent Y-o-Y) to Rs 2190 crore, according to HDFC Securities.

  • Glenmark Q3 PAT seen up 62.6% to Rs 363.5 cr: ICICI Securities Jan 16, 2017 12:17 PM IST

    Glenmark Q3 PAT seen up 62.6% to Rs 363.5 cr: ICICI Securities

    Net Sales are expected to increase by 11.6 percent Q-o-Q (up 39.6 percent Y-o-Y) to Rs 2482.5 crore, according to ICICI Securities.

  • Expect better performance from core US biz in Q3: Glenmark Oct 28, 2016 10:35 AM IST

    Expect better performance from core US biz in Q3: Glenmark

    Glenn Saldanha says Zetia Generic - a drug to keep a check on cholestrol levels - will be launched on December 12. The launch could see USD 200-250 million in revenues. The company is going to use the money from here to bring down company's debt.

  • Glenmark Pharma Q2 profit seen up 24% but margin may contract Oct 26, 2016 06:56 PM IST

    Glenmark Pharma Q2 profit seen up 24% but margin may contract

    Glenmark Pharma is expected to report a 24 percent growth in second quarter profit at Rs 245 crore on yearly basis but margin may contract by 160 basis points to 19.4 percent, according to analysts polled by CNBC-TV18.

Sections